Loong Herbert H, Ma Brigette B, Chan Anthony T
Department of Clinical Oncology, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR.
Hematol Oncol Clin North Am. 2008 Dec;22(6):1267-78, x. doi: 10.1016/j.hoc.2008.08.012.
Despite being potentially curable at an early stage, more than 50% of patients who have nasopharyngeal carcinoma present with advanced locoregional disease, which results in a poor prognosis. This article discusses key advancements in the management of nasopharyngeal cancer, including the incorporation of concurrent chemoradiotherapy, new radiotherapy delivery techniques in the form of conformal and intensity-modulated radiotherapy, and salvage options for locoregional recurrence. New cytotoxic and targeted therapies that have resulted in improved survival in the metastatic setting are also described. The use of Epstein-Barr virus DNA for the prognostication and monitoring of nasopharyngeal cancer and the role of new diagnostic imaging techniques are also discussed.
尽管鼻咽癌在早期可能治愈，但超过50%的鼻咽癌患者就诊时已出现局部区域晚期疾病，导致预后不良。本文讨论了鼻咽癌治疗的关键进展，包括同步放化疗的应用、适形放疗和调强放疗形式的新放疗技术，以及局部区域复发的挽救治疗选择。还描述了在转移性情况下已提高生存率的新细胞毒性和靶向治疗。此外，还讨论了爱泼斯坦-巴尔病毒DNA在鼻咽癌预后评估和监测中的应用以及新诊断成像技术的作用。
